4,739 Shares in Becton, Dickinson and Company $BDX Purchased by Inceptionr LLC

Inceptionr LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,739 shares of the medical instruments supplier’s stock, valued at approximately $745,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $25,000. Steph & Co. grew its position in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the period. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. raised its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. Finally, Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $29,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,188 shares of company stock valued at $765,120. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Up 2.2%

Shares of BDX stock opened at $156.26 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The firm has a market capitalization of $43.06 billion, a PE ratio of 39.56, a PEG ratio of 10.82 and a beta of 0.21. The stock has a fifty day simple moving average of $149.95 and a two-hundred day simple moving average of $164.97.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Barclays increased their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $180.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.